LPTX Leap Therapeutics Inc.

+0.02  (+1%)
Previous Close 2.03
Open 2.07
Price To Book 2.77
Market Cap 47,267,617
Shares 23,057,374
Volume 69,624
Short Ratio
Av. Daily Volume 215,524

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 data due 4Q 2019.
TRX518 in combination with gemcitabine chemotherapy or KEYTRUDA or Opdivo
Advanced solid tumors
Phase 1/2 data due July 2019.
Esophagogastric adenocarcinoma
Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.
Biliary tract cancer (BTC)
Phase 2 updated data due September 2019.
DKN-01 and Paclitaxel
Endometrial Cancer
Phase 1/2 trial to be initiated.
TRX518 and avelumab
Solid tumors

Latest News

  1. Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital
  2. Leap Therapeutics to Present at the 2019 Raymond James Life Sciences and MedTech Conference
  3. Investors Who Bought Leap Therapeutics (NASDAQ:LPTX) Shares A Year Ago Are Now Down 82%
  4. Leap Therapeutics Reports First Quarter 2019 Financial Results
  5. Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference
  6. Leap Therapeutics Reports Clinical Update and 2018 Financial Results
  7. Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer
  8. Four Tech Stocks Setting The Pace On Monday
  9. Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer
  10. Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of ...
  11. Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
  12. Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants
  13. Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
  14. 2 Small-Cap Biotech Stocks That Are on My Radar
  15. Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019
  16. Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
  17. Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer
  18. Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
  19. Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting
  20. Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress